Mending a broken heart with biotech

Beyond Biotech - the podcast from Labiotech

French company CellProthera has seen some remarkable results treating people who have had a heart attack. On this week’s podcast, the company’s CEO Matthieu de Kalbermatten tells us how it works.

01:00-03:29: About CellProthera
03:30-06:30: What are ProtheraCytes?
06:30-09:02: Is this a cure?
09:02-10:24: Is prevention the best option?
10:25-11:49: Is this therapy useful to treat other conditions?
11:50-13:55: How quickly do you need to treat a patient?
13:56-16:39: The field of regenerative therapy
16:39-17:52: Is regenerative therapy a growing sector?
17:53-18:26: Clinical trials
18:26-19:22: Upcoming phase 3 trials
19:22-20:36: The regulatory pathway
20:37-23:25: Cost and scale
23:25-24:20: The need for partnerships
24:21-24:57: Next steps
24:57-28:30: Is there excitement in the medical field for this treatment?
Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here!

Stay updated by subscribing to our newsletter

Kapitler

1. Mending a broken heart with biotech (00:00:00)

2. The history of CellProthera (00:01:00)

3. What are ProtheraCytes? (00:03:30)

4. Is this a cure? (00:06:30)

5. Is prevention the best option? (00:09:02)

6. Is this process useful in other conditions? (00:10:25)

7. How quickly do you need to treat a patient? (00:11:50)

8. The field of regenerative therapy (00:13:56)

9. Is regenerative therapy a growing sector? (00:16:39)

10. Clinical trials (00:17:53)

11. Upcoming phase 3 trials (00:18:26)

12. The regulatory pathway (00:19:22)

13. Cost and scale (00:20:37)

14. The need for partnerships (00:23:25)

15. What are the next steps? (00:24:21)

16. Is there excitement in the medical field for this treatment? (00:24:57)